Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Rastogi, Priya; O'Shaughnessy, Joyce; Martin, Miguel; Boyle, Frances; Cortes, Javier; S. Rugo, Hope; P. Goetz, Matthew; P. Hamilton, Erika; Huang, Chiun-Sheng; Senkus, Elzbieta; Tryakin, Alexey; Cicin, Irfan; Testa, Laura; Neven, Patrick; Huober, Jens; Shao, Zhimin; Wei, Ran; André, Valérie; Munoz, Maria; San Antonio, Belen; Shahir, Ashwin; Harbeck, Nadia; Johnston, Stephen

doi:10.1200/jco.23.01994

Public

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

Shared by NobleBlocks on Mar 20, 2024 • 12:00 AM UTC

Authors:

Priya Rastogi

Joyce O'Shaughnessy

Miguel Martin

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate ...

Discussions